Thermo Fisher bags single-use bioreactor tech partner Finesse

By Dan Stanton

- Last updated on GMT

Image: iStock/designer491
Image: iStock/designer491

Related tags Thermo fisher Life Technology Biology

Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.

The deal announced yesterday, adds bioprocess management technology Finesse Solutions to Thermo Fisher’s life sciences business.

CEO Marc Casper said the Santa Clara, California-based firm has been a technology partner since 2013, and its universal control system which combines with Thermo Fisher’s own single-use technologies will “strengthen our position in the high-growth bioproduction market.”

Finesse’s Smart technology suite offers a range of data management software, and bioreactor controllers and sensors which allow bioprocessing firms and drugmakers to configurate biomanufacturing processes from labscale to cGMP-compliant production.

Finesse generated around $50m in revenue last year. Financial details of the deal were not divulged, but Thermo Fisher expects the deal to close in the next few days, having received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.


The deal is the latest in a string of acquisitions made in the life science space by Thermo Fisher.

Last year the firm bought biological analysis firm Affymetrix​ for $1.3bn, analytical instrument firm FEI Company​ for $4.2bn, and stem cell tech and reagent business MTI-GlobalStem​. 2015 saw the company add disposable technology firm ASI to its bioprocessing arsenal for $300m, and a year earlier Life Technologies​ was acquired for $13bn.

Thermo Fisher was also rumoured to be interested in buying downstream disposable tech firm Pall Corporation – since acquired by Danaher for $13bn​ – and last summer was allegedly eyeing up Illumina for $30bn​.

During a call to discuss its Q4 results late last month, Casper told investors his firm continued to look at a number of M&A opportunities.

“The industry is incredibly fragmented,”​ he said. “So we follow our strategy of looking at things that will strengthen the company strategically, clearly be understood and valued by our customers and create shareholder value, with the primary metric being return on invested capital.”

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more